BioData World Congress 2016
BioData World Congress 2016
BioData World Congress is a world-leading event for individuals working with 'big data' and precision medicine. With the advent of high-powered computing architecture and plummeting costs of sequencing, a new era has begun, with large-scale initiatives like the 100,000 Genomes Project taking centre stage in global efforts to usher genomics into the clinic. Welcoming in this new generation of healthcare is a multifaceted effort requiring academics, commercial businesses, clinicians and pharmaceutical companies and of course the patients to congress and discuss how to develop this new exciting field of healthcare.
BioData World Congress 2016 is supported by EMBL-EBI, the Wellcome Trust Sanger Institute, the Global Alliance for Genomics and Health and the Pistoia Alliance.
The event will showcase innovation, demonstrate success and explore the main obstacles to translating innovations in genomics to solutions that improve the lives of patients. The programme comprises keynote presentations, round-table discussions, focused work tracks, site visits, product demonstrations and networking parties.
The full agenda for BioData World Congress 2016 is on the official website.
A full list of speakers is available on the official website. Speakers from the Wellcome Genome Campus include:
- Ewan Birney, Director, EMBL-EBI
- Laura Clarke, Vertebrate Data Coordinator, EMBL- EBI,
- Tim Hubbard, Head of Bioinformatics, Genomics England
- Joanne Mason, Director of Sequencing and Sample Acquisition, Genomics England
- Dr Anna Middleton, Head of Social Science and Ethics’, Wellcome Trust Sanger Institute
- Effie Mutasa-Gottgens, Senior Scientific Officer, EMBL-EBI
- Philippe Sanseau, Head Computational Biology Department, GSK (Open Targets)
- Serena Scollen, Head of Human Genomics and Translational Data, ELIXIR
- Oliver Stegle, Research Group Leader, EMBL-EBI
- Clare Turnbull, Clinical Lead for 100,000 Genomes Project, Genomics England
- Dr Julia Wilson, Associate Director, Wellcome Trust Sanger Institute
- Dr Eleftheria Zeggini, Group Leader, Wellcome Trust Sanger Institute
- How to manage data generated in bioinformatics
- How to utilise NGS to develop more targeted therapeutics
- How to apply genomic data in precision medicine
- Utilising cloud technology for collaborative research
- Developing secure information systems
- Ethical considerations in the sharing of genomic data
- How to transition big data into the clinic
- How to access open-source technologies in LS research
- Big data analytics and information mining.
Ewan Birney is Director of EMBL-EBI with Dr Rolf Apweiler, and runs a small research group. He is also EMBL-EBI's Joint Head of Research, alongside Dr Nick Goldman.
Ewan completed his PhD at the Wellcome Sanger Institute with Richard Durbin. In 2000, he became Head of Nucleotide data at EMBL-EBI and in 2012 he took on the role of Associate Director at the institute. He became Director of EMBL-EBI in 2015. Ewan led the analysis of the Human Genome gene set, mouse and chicken genomes and the ENCODE project, focusing on non-coding elements of the human genome. Ewan’s main areas of research include functional genomics, DNA algorithms, statistical methods to analyse genomic information (in particular information associated with individual differences in humans and Medaka fish) and use of images for chromatin structure.
Ewan is a non-executive Director of Genomics England, and a consultant and advisor to a number of companies, including Oxford Nanopore Technologies, Dovetail Genomics and GSK. Ewan was elected an EMBO member in 2012, a Fellow of the Royal Society in 2014 and a Fellow of the Academy of Medical Sciences in 2015.
He has received a number of awards including the 2003 Francis Crick Award from the Royal Society, the 2005 Overton Prize from the International Society for Computational Biology and the 2005 Benjamin Franklin Award for contributions in Open Source Bioinformatics.
Laura Clarke leads EMBL-EBI's efforts to build the Data Coordination Platform for the Human Cell Atlas (HCA). The HCA team at EMBL-EBI is primarily responsible for developing the ingest infrastructure and supporting its use. The ingest infrastructure writes data and metadata into the HCA Data Coordination Platform enabling its analysis and accessibility by the community.
Laura studied bioinformatics at Leeds University before joining the Ensembl project in 2001 at the height of the Human Genome Project. She created the primary gene sets associated with the rat, macaque and platypus genomes before moving to EMBL-EBI to establish data coordination for the 1000 Genomes Project. Since then Laura has led data coordinaton efforts for many large consortia such as Blueprint, HipSci and FAANG and continues in these efforts for the Human Cell Atlas.
Anna Middleton is an entrepreneurial researcher who designs and delivers cutting-edge social science research for the Wellcome Genome Campus. Her work explores the social and ethical impact of genomics on people, continually asking - how is society responding to genomic technology? Anna utilises both quantitative and qualitative research methods to gather empirical data on attitudes, beliefs and values about genomics. She is a subject matter expert on ethics for Health Education England's training for all health professionals taking consent for the 100k Genomes Project, and an experienced genetic counsellor who has co-written the core curriculum for genetic counselling training in the UK. Anna is Vice-chair of the Association of Genetic Nurses and Counsellors in the UK and ROI. Her proudest achievement is being the first person to publish empirical data on the attitudes of Deaf parents towards using pre-natal testing for deafness, with the preference for having deaf children. Anna Middleton is also the author of the Genome Ethics blog.
Dr Philippe Sanseau is Head of Computational Biology at GSK. He has a PhD from University of Rennes in France and conducted his postdoctoral training at the Imperial Cancer Research Fund in London (now Cancer Research UK), with a focus on immunogenetics. He joined GSK to work initially in the Genetics and Genomics Departments. Since 2001 he has held various senior roles in bioinformatics and computational biology. Philippe is currently leading the Computational Biology (CB) Department at GSK with scientists located in the UK and US. The CB Department is working on multiple therapeutic areas supporting drug discovery and development projects at all phases of the pipeline using diverse bioinformatics approaches applied to biomedical internal and external data. The Department maintains a strong scientific innovation agenda as demonstrated by our activities in target validation, drug repositioning, systems approaches, or microbiome analyses. CB at GSK has also developed an international network of academic collaborators and maintains a strong publication record. Philippe is a member of several international advisory boards and different UK and international funding committees.
PhD in Physics, University of Cambridge, 2009. Postdoctoral Fellow, Max Planck Institutes Tübingen, 2009–2012. Research Group Leader at EMBL-EBI since 2012.
Professor Ele Zeggini
Ele's work aims to help elucidate the genetic determinants of complex human traits by using next-generation association studies to identify novel disease loci. Ele obtained a BSc in Biochemistry from the University of Manchester Institute of Science and Technology (UMIST) in 1999 and a PhD in Immunogenetics of Juvenile Arthritis from the arc Epidemiology Unit, University of Manchester, in 2003. She then undertook a brief statistical genetics post doc, focusing on rheumatic disorders, at the Centre for Integrated Genomic and Medical Research, University of Manchester, before moving to the Wellcome Trust Centre for Human Genetics, University of Oxford, to work on the genetics of type 2 diabetes. In 2006, Ele was awarded a Wellcome Trust Research Career Development Fellowship to examine design, analysis and interpretation issues in large-scale association studies. She joined the Wellcome Trust Sanger Institute Faculty in November 2008 and leads the Analytical Genomics of Complex Traits group. Ele's scientific interests focus on the genetics of complex traits, primarily cardiometabolic and musculoskeletal phenotypes, and on addressing relevant statistical genetics issues.